Suggested remit: To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 1237
Provisional Schedule
- Committee meeting:
- 14 April 2026
- Expected publication:
- 06 August 2026
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email TACommA@nice.org.uk
- External Assessment Group:
- Newcastle NIHR TAR Team, Newcastle University
Stakeholders
- Companies sponsors
- GlaxoSmithKline
- Others
- NHS England
- Department of Health and Social Care
- Patient carer groups
- Asthma & Lung UK
- Professional groups
- Association of Respiratory Nurses
- British Thoracic Society
- Comparator companies
- Sanofi
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 September 2025 | Invitation to participate |
| 03 September 2025 | In progress. Progress STA |
| 27 August 2025 | In progress. Appraisal STA process |
| 06 June 2025 | Awaiting development. Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early September 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early November 2025. |
| 22 April 2025 - 21 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1237 |
| 22 April 2025 | In progress. Scoping commenced. |
| 23 October 2024 | Note - Note added to the project documents |
| 10 August 2023 | Note - Note added to the project documents |
| 13 December 2018 | Note added to the project documents |
| 20 September 2017 - 18 October 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual